Clinical Trials
121 trialsDLI-NK
Institut Paoli-Calmettes
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
VEN-OM
University of Illinois at Chicago
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Constellation Pharmaceuticals
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
Emory University
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
Novartis
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
Kangpu Biopharmaceuticals, Ltd.
A Study of DT2216 in Relapsed/Refractory Malignancies
Dialectic Therapeutics, Inc
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
MAPSS
Baylor College of Medicine
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
Biohaven Pharmaceuticals, Inc.
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CAR-37 T Cells in Hematologic Malignancies
Massachusetts General Hospital
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Astellas Pharma Inc
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
Innovent Biologics (Suzhou) Co. Ltd.
MK-1026-007
Merck Sharp & Dohme LLC
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
Precision BioSciences, Inc.
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
A Study Of PF-04449913 In Select Hematologic Malignancies
Pfizer
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Ohio State University Comprehensive Cancer Center
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Chinese PLA General Hospital
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
A Trial of ZL-1201 in Subjects With Advanced Cancer
Zai Lab (Hong Kong), Ltd.
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
Duke University
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Ascentage Pharma Group Inc.
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Opna Bio LLC
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
Zhejiang University
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Celgene
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
Safety of Romiplostim (Nplate®) Following UCBT
Masonic Cancer Center, University of Minnesota
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Stanford University
Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
Janssen Research & Development, LLC